[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579652":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":40,"locations":11,"responsibleParty":46,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":65,"conditions":66,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":11},{"fullName":5,"class":6},"Mianyang Central Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"161Tb-NY032","EXPERIMENTAL",null,[13,14,15,16,17],"Drug: 30 mCi NYMO32","Drug: 50 mCi NYMO32","Drug: 80 mCi NYMO32","Drug: 130 mCi NYMO32","Drug: 200 mCi NYMO32",[19,24,28,32,36],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","30 mCi NYMO32","The initial dose is set at 30 mCi.",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"50 mCi NYMO32","The dose will be escalated to 50 mCi.",[9],{"type":20,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"80 mCi NYMO32","The dose will be escalated to 80 mCi.",[9],{"type":20,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"130 mCi NYMO32","The dose will be escalated to 130 mCi.",[9],{"type":20,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"200 mCi NYMO32","The maximum dose is set at 200 mCi.",[9],[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"ZhengGuo Chen ZGC ZhengGuo Chen","CONTACT","0816-2226753","86753979@qq.com",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Zhengguo Chen","Chief Physician","100579652","phase-1-study-on-the-safety-tolerability-and-preliminary-efficacy-of-161tb-nym032-in-patients-with-metastatic-castration-resistant-prostate-cancer-100579652",false,"NCT06827080","Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer","\\*\\*1. Inclusion Criteria\\*\\*\n\n1. The participant voluntarily signs the informed consent form and is able to complete the trial according to the protocol requirements.\n2. Male, aged 18 years or older.\n3. Diagnosed with metastatic castration-resistant prostate cancer (mCRPC) as per PCWG3 criteria.\n4. Positive results on 68Ga-NYM032 positron emission tomography (PET)\u002Fcomputed tomography (CT) scan.\n5. Must have received at least one NAAD treatment (e.g., enzalutamide and\u002For abiraterone) or at least one taxane-based treatment regimen, or be intolerant to or refuse taxane therapy for metastatic castration-resistant prostate cancer.\n6. ECOG performance status of 0-2.\n7. Expected survival of ≥6 months.\n8. Laboratory parameters must meet the following:\n\n   1. ALT and AST must not exceed 3 times the upper limit of normal (ULN); BUN and Cr must not exceed 1.5 times the ULN.\n   2. Blood counts: WBC ≥3.5×10\\^9\u002FL, PLT ≥100×10\\^9\u002FL, Hb ≥90 g\u002FL.","MALE","18 Years",{"count":59,"type":60},15,"ESTIMATED","INTERVENTIONAL",[63,64],"PHASE1","PHASE2","161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.",[67,68],"Metastatic Castration-resistant Prostate Cancer, MCRPC","Cancer","NOT_YET_RECRUITING","2025-02-10",{"date":72,"type":73},"2025-02-14","ACTUAL",{"date":75,"type":60},"2025-02-11",{"date":77,"type":60},"2026-12-01",{"name":48,"class":6}]